5DG.F OCUMENSION THER.DL-00001
- Market cap
- EUR 443M
- P/E
- -
- P/B
- 0.92x
- ROE
- -4.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is 5DG.F undervalued?
Graham numberThe Graham number of OCUMENSION THER.DL-00001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
OCUMENSION THER.DL-00001 fundamental analysis
No fundamental analysis for OCUMENSION THER.DL-00001 yet.
OCUMENSION THER.DL-00001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About OCUMENSION THER.DL-00001
Ocumension Therapeutics, together with its subsidiaries, engages in the research, discovery, development, and commercialization of ophthalmic therapies in China. The company offers various ophthalmic drugs for the treatment of chronic non-infectious uveitis, wet age-related macular degeneration, diabetic macular edema, choroidal neovascularization, dry eye disease, glaucoma, allergic and bacterial conjunctivitis, fungus disease, and anti-inflammatory, as well as postoperativ…
Full company profileOCUMENSION THER.DL-00001 financial statements
OCUMENSION THER.DL-00001 annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 56.1M | 159M | 246M | 417M | 804M |
| Gross Profit | 36.9M | 103M | 144M | 225M | 361M |
| Operating Income | -386M | -448M | -401M | -304M | -157M |
| EBITDA | - | -360M | -321M | -176M | -12.3M |
| Net Income | -260M | -403M | -380M | -268M | -159M |
| EPS | -0.39 | -0.58 | -0.57 | -0.33 | -0.20 |
| Balance Sheet | |||||
| Total Assets | 3.33B | 3.04B | 3.27B | 3.97B | 4.09B |
| Total Liabilities | 223M | 295M | 351M | 200M | 410M |
| Shareholders' Equity | 3.11B | 2.75B | 2.92B | 3.77B | 3.68B |
| Cash & Short-term Investments | 1.13B | 1.17B | 843M | 729M | 377M |
| Cash Flow | |||||
| Operating Cash Flow | -197M | -201M | -178M | -179M | -105M |
| Capital Expenditure | 665M | 310M | 362M | 230M | 253M |
| Free Cash Flow | -862M | -511M | -540M | -409M | -359M |
| Ratios | |||||
| ROE | -8.4% | -14.6% | -13.0% | -7.1% | -4.3% |
| ROA | -7.8% | -13.2% | -11.6% | -6.8% | -3.9% |
| Net Profit Margin | -463.1% | -253.3% | -154.2% | -64.3% | -19.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
OCUMENSION THER.DL-00001 dividends
OCUMENSION THER.DL-00001 has not paid dividends in the last 5 fiscal years.
Who owns OCUMENSION THER.DL-00001
- Insiders 47.06%
- Institutions 12.74%
- Public & others 40.20%
- Shares outstanding 799M
- Free float 353M
OCUMENSION THER.DL-00001 company profile
- Company name
- OCUMENSION THER.DL-00001
- Ticker
- 5DG.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 608
- Fiscal year end
- June
- Address
- No. 1858 Yinzhongnan Road, Suzhou, China
- Website
- ocumension.com
About OCUMENSION THER.DL-00001
Ocumension Therapeutics, together with its subsidiaries, engages in the research, discovery, development, and commercialization of ophthalmic therapies in China. The company offers various ophthalmic drugs for the treatment of chronic non-infectious uveitis, wet age-related macular degeneration, diabetic macular edema, choroidal neovascularization, dry eye disease, glaucoma, allergic and bacterial conjunctivitis, fungus disease, and anti-inflammatory, as well as postoperative ocular inflammation, paralysis of ciliary muscle, and pupil dilation, as well as eyelid and periocular cleansing. It also develops drugs in Phase III clinical trial, including OT-101 for myopia, OT-802 for presbyopia, OT-211 for dry eye disease, and OT-301 for glaucoma; and drugs in Phase I/II clinical trial, such as OT-703 for diabetic macular edema, OT-202 for dry eye disease, and OT-601-C for the treatment of ocular inflammation. In addition, the company engages in the development of drugs in preclinical stage comprising OT-701 for wet age-related macular degeneration, OT-1601 for retinitis pigmentosa and dry age-related macular degeneration, OT-1602 for optic neuritis, and OT-503 for dry eye disease. Further, it is involved in trading of pharmaceutical products; and plant construction. The company was founded in 2017 and is based in Suzhou, China.
OCUMENSION THER.DL-00001 management
6- Mr. Ye LiuCEO & Executive Director · born 1971
- Mr. Qinglei ZuoChief Commercial Officer · born 1984
- Dr. Yang ShenChief Medical Officer · born 1983
- Ms. Hongying LiuChief Manufacturing Officer and Head of Manufacture · born 1978
- Dr. Shenyang .Chief Medical Officer
- Ms. Tingchan ChenCompany Secretary · born 1995